A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/26 (2006.01) A61K 38/28 (2006.01) A61K 47/10 (2006.01) A61K 47/26 (2006.01) A61P 3/10 (2006.01)
Patent
CA 2358107
Glucagon-like peptide-1 (GLP-1) has been shown to be useful in the treatment of diabetes. The invention encompasses a shelf stable formulation that comprises a therapeutically effective amount of GLP-1, a pharmaceutically acceptable preservative, and a tonicity modifier, and that has a pH between about 8.2 to about 8.8.
On a démontré que le peptide-1 de type glucagon (GLP-1) est efficace dans le traitement du diabète. Cette invention concerne une formulation de longue conservation contenant une dose efficace du point de vue thérapeutique de GLP-1, un conservateur acceptable sur le plan pharmaceutique, un modificateur de tonicité, et présentant un pH compris entre environ 8,2 et environ 8,8.
Brader Mark Laurence
Pekar Allen Howard
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
Shelf-stable formulation of glucagon-like peptide-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Shelf-stable formulation of glucagon-like peptide-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Shelf-stable formulation of glucagon-like peptide-1 will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1557877